Limited Time Special Pricing - Act Now
Clinician groups further highlighted that lifestyle modifications alone are often insufficient to achieve the weight loss needed to improve obesity-related complications like T2DM and MASLD
I'm not really seeing a difference with my stomach or weight
From a cancer risk perspective, this pharmacokinetic profile offers some reassurance
However, the company faces intensifying competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound), which has demonstrated superior weight loss efficacy, reshaping prescriber preferences in obesity management [2]
doi: 10.3389/fphar.2025.1477127 Received 09 September 2024 Accepted 02 June 2025 Published 18 June 2025 Volume 16 - 2025 Edited by Anick Brard, Montreal University, Canada Reviewed by Raffaele Falsaperla, Policlinico San Marco, Italy Cristian Catalin Gavat, Grigore T